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ABSTRACT The process of genome release or uncoating after viral entry is one of the least-studied steps in the flavivirus life cy-
cle. Flaviviruses are mainly arthropod-borne viruses, including emerging and reemerging pathogens such as dengue, Zika, and
West Nile viruses. Currently, dengue virus is one of the most significant human viral pathogens transmitted by mosquitoes and
is responsible for about 390 million infections every year around the world. Here, we examined for the first timemolecular as-
pects of dengue virus genome uncoating. We followed the fate of the capsid protein and RNA genome early during infection and
found that capsid is degraded after viral internalization by the host ubiquitin-proteasome system. However, proteasome activity
and capsid degradation were not necessary to free the genome for initial viral translation. Unexpectedly, genome uncoating was
blocked by inhibiting ubiquitination. Using different assays to bypass entry and evaluate the first rounds of viral translation, a
narrow window of time during infection that requires ubiquitination but not proteasome activity was identified. In this regard,
ubiquitin E1-activating enzyme inhibition was sufficient to stabilize the incoming viral genome in the cytoplasm of infected
cells, causing its retention in either endosomes or nucleocapsids. Our data support a model in which dengue virus genome un-
coating requires a nondegradative ubiquitination step, providing new insights into this crucial but understudied viral process.
IMPORTANCE Dengue is the most significant arthropod-borne viral infection in humans. Although the number of cases increases
every year, there are no approved therapeutics available for the treatment of dengue infection, andmany basic aspects of the viral
biology remain elusive. After entry, the viral membrane must fuse with the endosomal membrane to deliver the viral genome
into the cytoplasm for translation and replication. A great deal of information has been obtained in the last decade regarding
molecular aspects of the fusion step, but little is known about the events that follow this process, which leads to viral RNA release
from the nucleocapsid. Here, we investigated the fate of nucleocapsid components (capsid protein and viral genome) during the
infection process and found that capsid is degraded by the ubiquitin-proteasome system. However, in contrast to that observed
for other RNA and DNA viruses, dengue virus capsid degradation was not responsible for genome uncoating. Interestingly, we
found that dengue virus genome release requires a nondegradative ubiquitination step. These results provide the first insights
into dengue virus uncoating and present new opportunities for antiviral intervention.
Received 4 May 2016 Accepted 26 May 2016 Published 28 June 2016
Citation Byk LA, Iglesias NG, De Maio FA, Gebhard LG, Rossi M, Gamarnik AV. 2016. Dengue virus genome uncoating requires ubiquitination. mBio 7(3):e00804-16. doi:10.1128/
mBio.00804-16.
Editor Vincent R. Racaniello, Columbia University College of Physicians & Surgeons
Copyright © 2016 Byk et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Address correspondence to Andrea V. Gamarnik, agamarnik@leloir.org.ar.
This article is a direct contribution from a Fellow of the American Academy of Microbiology. External solicited reviewers: Adolfo Garcia-Sastre, Icahn School of Medicine at
Mount Sinai; Karla Kirkegaard, Stanford University School of Medicine.
Dengue virus (DENV) belongs to the Flavivirus genus in theFlaviviridae family, together with other emerging and re-
emerging human pathogens that cause fever and encephalitis,
such as Zika virus (ZIKV), West Nile virus (WNV), Japanese en-
cephalitis virus (JEV), and Saint Louis encephalitis virus (SLEV).
DENV is the most prevalent mosquito-borne human viral
pathogen worldwide, with around 3.6 billion people currently liv-
ing in areas of endemicity. About 390 million infections in total
and 100 million symptomatic cases of DENV infection are esti-
mated to occur each year (1). In the Americas, a steady increase in
the number of DENV infections is being recorded, and areas for-
merly considered DENV free are registering the first outbreaks of
dengue fever due to the mobility of people from regions of ende-
micity and the presence of the Aedes aegypti vector (WHO; http:
//apps.who.int/iris/bitstream/10665/75303/1/9789241504034
_eng.pdf?ua1). Despite this great burden and the urgent
medical need to control DENV infections, effective therapeutics
are still unavailable.
DENV bears a plus-strand RNA genome of about 11 kb that
includes a single open reading frame. The genome is translated
into a single polyprotein that is cleaved into three structural pro-
teins (capsid, envelope [E], andmembrane [prM/M]) and at least
seven nonstructural proteins (2). In addition to serving as a mes-
senger for translation, the genome is a template for RNA replica-
tion and encapsidation. In the last decade, a great deal has been
learned about molecular mechanisms that regulate viral genome
replication (3). However, little is known about the processes that
lead to genome encapsidation and uncoating. These two funda-
mental viral steps involve opposite functions of the viral capsid
protein, whichmust recruit and release the genome during assem-
bly and uncoating, respectively.
The capsid protein is a highly basic protein of 12 kDa that binds
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RNA with high affinity but low specificity. The protein forms ho-
modimers in solution and oligomerizes upon nucleic acid bind-
ing. The tridimensional structure, solved by nuclearmagnetic res-
onance (NMR) analysis, indicates the formation of 4-helices (1
to 4) (4). Both the N-terminal region, unstructured in solution,
and the 4 helix contain clusters of positive charges that are es-
sential for RNA binding and particle assembly (5, 6). Viral particle
reconstructions have suggested that the capsid works as a nucleo-
protein that neutralizes and condenses the viral RNA without a
defined structure (7, 8).
Recent studies have focused on capsid functions for drug de-
velopment to control DENV infections (9–11). Although still little
explored, the capsid is an attractive target for antivirals due to the
multimeric assembly of the protein. On the basis of the concept of
genetic dominance of defective subunits, oligomerization of cap-
sid units, including both resistant and susceptible proteins, in in-
fected cells would generate nonfunctional complexes, delaying
emergence of resistant viruses (11).
In DENV-infected cells, capsid proteins distribute in different
subcellular compartments. They accumulate in the nucleus
(mainly in the nucleolus) and associate with lipid droplets (LDs)
and endoplasmic reticulum (ER) membranes (12–17). The func-
tional significance of the nuclear and LD accumulation of capsid is
still unclear. Viral assembly takes place in close association with
RNA replication complexes near ER membranes, where capsid
proteins presumably interact with the viral RNA to form the nu-
cleocapsid, which in turn buds into the ER, acquiring the lipid
bilayer containing E and prM/M. The immature viral particles
then travel through the secretory pathway and, after maturation
by furin activity, are released.
During a new infection, the viral particle is internalized by
receptor-mediated endocytosis and, upon endosome acidifica-
tion, conformational changes in the E protein lead to membrane
fusion (18, 19). This process results in the release of the viral nu-
cleocapsid into the cytoplasm, where the genome is used for trans-
lation. How the capsid protein is removed from the viral RNA and
how the genome is released to enable protein synthesis during
infection are still obscure steps in the biology of DENV and other
flaviviruses.
To examine the process of DENV genome uncoating, we ana-
lyzed the fate of capsid protein during infection.We describe here
for the first time the kinetics of the incoming capsid and found
that the protein is degraded after internalization by a ubiquitin-
proteasome-dependent process. Although capsid degradation
seemed to temporarily correlate with the initial rounds of viral
translation, genome uncoating was found to be independent of
the proteasome activity. Pharmacological inhibition of the protea-
some was sufficient to increase capsid stability but did not impair
nucleocapsid disassembly. Importantly, inhibition of the cellular
E1 ubiquitin-activating enzyme was found to avoid the liberation
of the incoming viral RNA during infection, impairing access of
the viral genome to the translation machinery. Our data provide
new insight into DENV uncoating and present new ideas for an-
tiviral intervention.
RESULTS
Fate of the incoming DENV capsid protein during viral infec-
tion. After DENV entry, the viral particle remains inside endo-
somes, and after endosomematuration andmembrane fusion, the
nucleocapsid is released into the cytoplasm (Fig. 1A). To study
these initial steps that lead to genome uncoating during DENV
infection, we first developed a protocol to detect the incoming
capsid protein in adsorbed and internalized virions.We examined
changes in capsid protein levels as a function of time after DENV2
infection of A549 cells by the use of Western blots. Capsids of
adsorbed viruses were readily detected by inoculation at 4°C
(Fig. 1B). To examine the internalized capsid protein, adsorbed
viruses were removed by proteinase K (PK) treatment. Cells kept
at 4°C and treated with PK showed complete removal of adsorbed
viruses (Fig. 1B). After the temperature was shifted to 37°C, inter-
nalized viruses were analyzed as a function of time, and adsorbed
(noninternalized) particles were removed at each time point by
PK treatment. The amount of capsid in infecting virions was a
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FIG 1 Fate of the capsid protein during DENV infection. (A) Schematic
representation of the events during viral entry and uncoating. (B) (Top) Ex-
perimental design showing the times of infection (above time line) and times
of sample collection (below time line). (Bottom) Western blots using DENV
anticapsid antibodies are shown. Adsorption lanes indicate the capsid protein
present in adsorbed virions in the absence of proteinase K (PK) treatment. In
the presence of PK, complete removal of adsorbed virions was observed. The
presence of the capsid protein during viral infection at different times from1 to
20 h postinfection after PK treatment is shown. (C) Levels of capsid protein
inside the host cell as a function of time postinfection in the presence (orange
bars) and absence (white bars) of cycloheximide (CHX). AU, arbitrary units.
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limitation for protein detection; thus, scaling up the amount of
infected cells was necessary for all the studies whose results are
described below. This assay allowed not only detection of capsid
protein that enters the cell during infection but also analysis of the
kinetics of protein levels during the whole viral life cycle. A time
course analysis postinfection showed the degradation of capsid
protein, with an estimated half-life of 90 min. Capsid was barely
detected after 4 h and remained undetectable until 8 h postinfec-
tion. At that time, an exponential increase in protein levels, rep-
resenting protein that was presumably newly synthesized as a re-
sult of genome amplification, was observed (Fig. 1B).
It is possible that the first rounds of translation contributed to
the first peak of capsid protein detected. To examine this possibil-
ity, we extended the time course to evaluate the levels of capsid
inside infected cells, in the presence or absence of cycloheximide
(CHX). The cellular translation is inhibited by the use of this com-
pound, allowing the detection of only the incoming capsid pro-
tein. The levels of capsid detected between 15 min and 4 h post-
DENV infection were not significantly different in the presence
and absence of the translation inhibitor (Fig. 1C). The second
peak of capsid accumulation was not detected in the presence of
CHX due to inhibition of RNA replication in the absence of viral
translation (Fig. 1C). This indicates that the translated capsid pro-
tein from the incoming viral genome does not significantly con-
tribute to the amount of detected protein during the first hours
postinfection. We conclude that capsid levels follow a biphasic
curve during infection, with the first peak corresponding to capsid
inside internalized virions and the second peak associated with
newly synthesized protein from amplified genomic RNA.
The incoming DENV capsid protein is subjected to
proteasome-dependentdegradation.Toexaminewhether capsid
degradation is proteasome dependent, we used a protocol similar
to the one described above but included the use of the proteasome
inhibitor MG132. Cells were infected with DENV2 and treated
with CHX to avoid detection of newly synthesized protein in the
presence or absence of MG132. A time course analysis of capsid
levels under these conditions showed a significant delay in protein
degradation, suggesting a proteasome-dependent process.We ob-
served that the half-life of the incoming capsid increased from
about 90 min to 5 h in the presence of MG132 (Fig. 2A). On the
basis of this observation, we hypothesized that DENV nucleocap-
sid disassembly requires proteasome activity for capsid degrada-
tion, similarly to that described for poxviruses (20).
An important method to assess genome release in the cyto-
plasm is measurement of the first rounds of translation, which
were undetectable byWestern blot analysis of capsid or other viral
proteins tested (Fig. 1C). Thus, we evaluated whether a reporter
virus carrying a luciferase gene was amenable to detection of early
translation of the incoming viral RNA. To this end, we used a
reporter system carrying the full-length viral genome fused to Re-
nilla luciferase that we had previously developed in our laboratory
(dengue virus R [DV-R]) (14). Infection with DV-R allowed de-
tection of translation, as distinguished from that occurring in the
presence of puromycin, as early as 2 h postinfection (Fig. 2B).
If capsid degradation is necessary for genome uncoating, the
first rounds of translation would be impaired by proteasome in-
hibition. Thus, we examined the impact of MG132 on translation
of the incoming genome using the DV-R system. Unexpectedly,
the viral RNA was readily available for translation in the presence
of the inhibitor. The measurements of translation at 4 and 6 h
postinfection were similar in the presence and absence of MG132
(Fig. 2C). The results support the idea that the incoming capsid
protein is degraded by a proteasome-dependent process; however,
this event is not required for genome release. We cannot rule out
the possibility of an active role of the ribosomes in displacing
capsid from the RNA (21), but it is possible to conclude that cap-
sid degradation is not the cause of DENV genome uncoating and
that protein decay likely takes place when the RNA is already en-
gaged in translation (Fig. 2D).
Ubiquitination is required for the initial rounds of DENV
translation. Considering that the proteasome pathway is typi-
cally ubiquitin dependent, we further evaluated whether ubiq-
uitination was necessary for incoming viral capsid degradation.
To this end, we examined whether inhibition of the ubiquiti-
nation machinery increased capsid stability during infection.
UBEI 41, an inhibitor of ubiquitin-like modifier activating en-
zyme 1 (UBA1), was used. DENV-infected cells were incubated
in the presence of CHX to avoid detection of newly synthetized
protein at late time points and were treated with UBEI 41 or left
untreated. Cell extracts were taken every hour and treated with
PK as previously described. A slight delay in viral entry was
observed, as the amount of capsid internalized was about 20%
less than that detected in the presence of dimethyl sulfoxide
(DMSO) (control). Importantly, a great impact on the stability
of the internalized capsid was observed in the presence of UBEI
41 (Fig. 3A). The half-life of capsid changed from 90 min to
about 6 h. The delay in protein degradation was similar to that
observed upon proteasome inhibition. These results support
the idea of a role of the ubiquitin-proteasome pathway in viral
capsid decay during DENV infection.
Then, we attempted to confirm that genome uncoating was
also independent of ubiquitination. Therefore, we used the re-
porter virus to measure early translation events. Cells were in-
fectedwithDV-R in the presence ofUBEI 41 orDMSO, and trans-
lation was analyzed as a function of time. Surprisingly, a
remarkable inhibition of viral translation was observed in the
presence of the ubiquitin E1 inhibitor (Fig. 3B). On the basis of
this result, it was possible that UBEI 41 exerted a direct effect on
viral translation. Thus, we bypassed the entry-uncoating step by
transfecting the viral RNA and translation was examined in the
presence or absence of UBEI 41. Under these conditions, transla-
tion was unaffected by E1 inhibition (Fig. 3C). To confirm this
result, we designed an additional control experiment in which
viral infection was performed in the absence of UBEI 41, viral
internalization and uncoating were allowed for 2 h, and the inhib-
itor was then added (Fig. 3D, left panel). These infected cells were
subsequently used to evaluate the impact of the inhibitor directly
on translation 6 h postinfection. Under these conditions, the
translation levels of cells treated with UBEI 41 or DMSO were
indistinguishable (Fig. 3D). Together, the results confirm that the
ubiquitin E1 enzyme activity is necessary during an early step in
DENV infection, after internalization but previous to viral trans-
lation. Interestingly, this requirement was found to be indepen-
dent of the proteasome activity (Fig. 2C).
To better define the window of sensitivity to UBEI 41, we per-
formed a time course, preincubating or adding the inhibitor, or
DMSO, at different times postinfection (5, 10, 30, and 120 min)
(Fig. 3E, left panel). An evident reduction of the effect of the drug
was observedwhen the inhibitor was added 30min after infection,
suggesting that the ubiquitination machinery is necessary early
Uncoating of Dengue Virus Genome
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during DENV infection (Fig. 3E). Because UBEI 41 does not im-
pair viral entry (Fig. 3A) or translation (Fig. 3D), we identified a
sensitive step during genome uncoating (postentry and pretrans-
lation) for DENV inhibition.
To further confirm the requirement of E1 activity for a produc-
tive infection, we silenced the protein target of UBEI 41 (UBA1)
using small interfering RNAs (siRNAs). Cells were transfected
with positive and negative siRNA controls or directed to UBA1.
After confirming a reduction of about 85% of the levels of UBA1
mRNA at 48 h posttransfection, cells were infected with DV-R,
and translation was measured at early time points to evaluate the
first rounds of translation. Under these conditions, silencing
UBA1 resulted in a 4-fold inhibition of viral translation similar to
that observed for the Renilla luciferase siRNA positive control
(Fig. 3F). The data confirm the requirement of E1 for an early
event during DENV infection.
The requirement of ubiquitination of proteins that participate
in maturation and trafficking of endosomes has been previously
described (22–24). For different viruses, including influenza and
vaccinia viruses, it has been shown thatmembers of the large fam-
ily of cullin-RING E3 ligases (CRL), such as Cullin3, are involved
in viral uncoating (20, 25). To examine whether this requirement
was common for DENV, we silenced a protein that has been
shown to be essential for the activity of these E3 ligases (reviewed
in reference 26) that neddylates themembers of theCRL family. In
this regard, siRNAs directed to UBA3, a component of the
NEDD8 E1-activating enzyme, were used to assess the impact on
DENV entry and translation. The results indicated that, in con-
trast to that observed by silencing UBA1, downregulation of
UBA3 did not affect the first rounds of DENV translation
(Fig. 3F). To confirm this observation by an alternative method, a
pharmacological inhibitor of neddylation, MLN 4924, which has
been reported to block the activity of members of the CRL family
of E3 ligases, was also used. In this experiment, cells were treated
with MLN 4924, UBEI 41, or DMSO and infected with DV-R.
Translation was unaffected by MLN 4924, further suggesting that
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FIG 2 Capsid protein decay is proteasome dependent, but its degradation is not required for initial viral translation. (A) A representativeWestern blot showing
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DENV does not require any CRL activity for genome uncoating
(Fig. 3G).
DENV containing a K-less capsid protein is competent for
uncoating. We found that capsid protein is degraded by the pro-
teasome but that this process is not required for genome release
into the cytoplasm. In addition, ubiquitin E1 activity was found to
be necessary for translation of the incoming viral genome but not
for viral internalization. It is possible that capsid ubiquitination
functions as a signal for nucleocapsid disassembly, as it was pre-
viously described for the disassembly of cellular ribonucleopro-
tein complexes (27). To evaluate whether capsid requires a non-
degradative ubiquitination step for RNA release during infection,
we generated recombinant DENVs in which the 11 Lys residues in
capsid (possible targets for ubiquitination) were partially or com-
pletely replaced by Arg. Six recombinant viruses with partial KR
replacement, and one virus carrying only Arg (K-less capsid) were
designed. (Fig. 4A, top panel). Cells were transfected with viral
RNAs corresponding to these mutants along with a parental
(wild-type [WT]) virus RNA, and viral propagationwas examined
by immunofluorescence (IF). Mutant 2 (Mut 2) and Mut 3 prop-
agated similarly to the WT, while Mut2 plus Mut3 (Mut23)
showed a slight delay in propagation. In contrast, all the genomes
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of themutants that included the substitution introduced intoMut
1 (Mut 1, Mut 12, Mut 13, and K-Less) showed either a pro-
nounced delay of or an impairment in viral propagation (Fig. 4A).
To further evaluate viral infection of these mutants, we examined
the level of expression of capsid protein for each case by Western
blot analysis (Fig. 4B). The results of this analysis correlated with
those of the IF assay. There are several possible explanations of
these results. It is possible that Lys residues at specific positions are
necessary forDENVassembly and/or infection, including possible
ubiquitination; however, because the capsid coding sequence con-
tains cis-acting RNA elements, an impact of the substitutions on
RNA structures and viral RNA synthesis is also possible.
To evaluate this last possibility, the KxRmutations were intro-
duced into a DENV reporter system, DV-RD (Fig. 4C, top panel).
RNA corresponding to the DV-RD K-less was transfected into
A549 cells together with two controls, theWT RNA and a replica-
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K substitutions were incorporated. (Bottom panel) Translation and replication of viral RNAs in reporter-transfected cells followed by luciferase activity
measurements. A WT virus, a K-less mutant, and a replication impaired control virus (Mut NS5 [polymerase mutant]) are shown. hpt, hours posttransfection.
(D) Schematic representation of the reporter dengue virus, DV-R, showing the locations of the mutations inserted in the capsid protein. (E) Translation and
replication of viral RNAs corresponding toWTDV-R, a capsid-deleted control (C), and the lysinemutants. (F) Evaluation of production of infectious particles.
Levels of luciferase activity measured postinfection with supernatants obtained from the transfections presented in panel E.
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tion impairedwith amutated polymerase (MutNS5). The levels of
translation of the three RNAs were indistinguishable; however,
RNA synthesis of the DV-RD K-less measured at 24 and 48 h
posttransfection was impaired (Fig. 4C), indicating that the intro-
duced nucleotide changes drastically affected genome replication.
These findings will be followed up in a separate study.
To evaluate the impact of the mutations exclusively on capsid
protein functions, we used a different reporter virus which con-
tains a duplication of the cis-acting RNA elements and introduced
all the mutations in the coding sequence of capsid protein
(Fig. 4D). Transfection of the mutated viral RNAs indicated that
translation and RNA replication were efficient, confirming the
successful uncoupling of RNA replication and capsid functions
(Fig. 4E). To evaluate newly generated viral particles and to test
their infectivity, the medium from transfected cells was used to
infect fresh cells and luciferase activity was evaluated. If Lys ubiq-
uitination is a requirement for viral uncoating, the K-less virus
would not be infectious. AlthoughMut 13 and theK-less viruses
showed some reduction in infectivity, they retained the ability to
produce particles and to infect new cells. In addition, the other
mutants showed infection levels similar to those seen with theWT
virus (Fig. 4F). Together, the results suggest that genome uncoat-
ing does not depend on Lys ubiquitination of capsid. The possi-
bility of capsid ubiquitination at noncanonical residues cannot be
excluded.
Ubiquitination inhibition blocks DENV genome release
during infection.To further study the requirement of ubiquitina-
tion for viral uncoating, we examined the fate of the incoming
viral genome during DENV infection and evaluated the impact of
UBA1 inhibition. Viral RNA was quantified during the complete
viral life cycle. The pattern of RNA levels as a function of time
postinfection was strikingly similar to that observed for capsid
protein (compare Fig. 5A with Fig. 1C). The highest level of in-
coming genomewas detected between 1 and 2hpostinfection, and
then the level dropped. Taking into account the translation kinet-
ics, the incoming genome was uncoated, translated, and mostly
degraded within a few hours after entry. Less than 5% of the in-
coming genome remained at 4 h postinfection. This RNA serves as
the substrate for RNA amplification, which leads to an exponen-
tial increase in RNA levels (Fig. 5A, left panel). To evaluate the
impact of ubiquitin E1 inhibition on the fate of the viral RNA, cells
treatedwithUBEI 41were infected andRNA levels were examined
as described above. Interestingly, the viral RNA was internalized
under these conditions, but levels remained the same even at 10 h
postinfection (Fig. 5A, right panel). This result indicates that ge-
nome uncoating/degradation is avoided by inhibition of E1 activ-
ity. The data confirm the requirement of a ubiquitination step for
genome release either from endosomes or nucleocapsids and ex-
plain why the first rounds of viral translation were impaired in the
absence of ubiquitination (Fig. 5B).
DISCUSSION
The mechanism by which the viral genome is released from the
nucleocapsid during infection is one of the least-characterized
processes of the flavivirus life cycles. Here, we determined that
ubiquitination but not proteasome activity is crucial for DENV
RNA release into the cytoplasm from incoming virions.We found
that capsid protein degradation is proteasome dependent but that
its decay is not the cause of genome uncoating. Our observations
support a model in which capsid protein degradation takes place
independently of the engagement of the viral genome in viral
translation. Importantly, we demonstrated that inhibition of the
ubiquitin E1 activity blocks genome uncoating, resulting in a pro-
tected/inactive viral RNA retained inside either endosomes or nu-
cleocapsids. These results provide the first insights into the DENV
uncoating process and highlight a window of opportunity for viral
inhibition.
In the last few years, studies on DNA and RNA viruses have
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FIG 5 Ubiquitination inhibition blocks viral genome release during infection. (A) Levels of viral RNA measured by real-time RT-PCR as a function of time
postinfection of cells treated with DMSO (left panel [Control]) or UBEI 41 (right panel). Adsorbed viral particles were removed with PK treatment at all time
points. Data correspond to the averages of results of triplicates, and error bars indicate standard deviations. (B) Cartoon representing the steps of the viral life
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uncovered unconventional modes of utilization of the host ubiq-
uitin proteasome system for viral uncoating. Mercer and collabo-
rators showed that vaccinia virus genome release from the core
protein required proteasome activity; however, the process was
ubiquitination independent. Interestingly, it was found that the
core protein was already ubiquitinated inside the viral particle
(20). For influenza A virus (IAV), ubiquitin was recently reported
to be crucial for viral uncoating; unexpectedly, capsid proteinwith
non-covalently attached ubiquitin chains was found in the virion
(28). In addition, Su and collaborators identified the E3 ubiquitin
ligase Itch as a fundamental factor for an early stage in the IAV life
cycle (24). They found that the incorporation of viral ribonucle-
oprotein complex into endosomes in Itch knockdown cells was
normal but that its subsequent release from endosomes was re-
tarded.Here, we describe forDENV yet another way of employing
the ubiquitin/proteasome system in which a nondegradative
ubiquitination step is necessary to release the viral genome into
the cytoplasm. By using pharmacological inhibition of the ubiq-
uitin E1, or UBA1 silencing, DENV infection was blocked (Fig. 3).
In this regard, an upregulation of UBA1 expression upon DENV
infection in primary human cells has been previously noticed,
supporting the idea of viral utilization and regulation of this host
protein (29). Moreover, in the same study, a reduction in DENV
titers was detected by UBA1 inhibition. Our observations are in
agreement with the results of that previous study and provide an
explanation for the reduced viral propagation reported.
The requirement of ubiquitination during flavivirus infection
was previously proposed based on RNA interference screens (30).
In that study, a requirement of the ubiquitin ligase CBLL1 in
WNV internalization was found. The authors reported that inhi-
bition of the proteasome activity abolished WNV infection; how-
ever, another group observed that CBLL1 depletion did not affect
DENV orWNVparticle internalization (31). Moreover, those au-
thors claimed that neither the presence of MG132 nor that of
lactacystin inhibitedWNV genome entry, suggesting that the pro-
teasome systemwas not required for early stages of infection (31).
Our observations using DENV support the idea that MG132 does
not affect viral internalization, uncoating, or early viral translation
(Fig. 2). Moreover, by silencing or inhibiting the activity of the
CRL family of E3 ligases, we excluded the requirement of this large
group of ligases for DENV genome release (Fig. 3). Although dif-
ferences between DENV and WNV infections have been noticed,
it will be important to examine whether early steps inWNV infec-
tion also require a ubiquitination step that is independent of the
proteasome activity.
Initially, we hypothesized that the incoming capsid protein
could be subjected to ubiquitination as a signal for uncoating. In
this regard, it has been reported that the host valosin-containing
protein (VCP) (p97) disassembles ribonucleoprotein complexes
by detecting ubiquitinated proteins (27). On the basis of this pos-
sibility, we attempted to detect ubiquitination of the capsid pro-
tein that enters the cell in virions. Although we used different
assays, the analysis was hampered by the small amounts of capsid
involved and the narrow window of time for detecting the incom-
ing protein. Thus, as an alternative strategy, we developed recom-
binant dengue viruses with Lys replaced by Arg in the capsid
protein. This strategy was complicated due to the presence of cis-
acting RNA replication elements in the capsid coding sequence.
To overcome this problem, we used a reporter DENV with dupli-
cated capsid coding regions to uncouple RNA genome replication
and virus production. Using this system, we generated a virus with
a K-less capsid that, although less efficient than the WT, was able
to produce infectious particles (Fig. 4). The fact that a DENV
bearing a K-less capsid is able to infect cells suggests that capsid is
not the target for the ubiquitination required for uncoating.
Our results show that the incoming viral RNA increased its
half-life from 3 h to more than 10 h in the presence of the ubiqui-
tin E1 inhibitor, supporting the idea that ubiquitination was nec-
essary for genome release into the cytoplasm. Considering that the
ubiquitin inhibitor does not impair viral entry and that its effect
on translation was observed only if it was added at up to 30 min
after infection, we propose that ubiquitination is necessary during
endosome maturation, membrane fusion, or nucleocapsid disas-
sembly (Fig. 5). Thus, we conclude that ubiquitination is required
postentry and pretranslation.
For different viruses, interference with capsid protein func-
tions can greatly disturb genome release during viral entry, abol-
ishing viral infection. This explains why the capsid proteins of
enveloped viruses have been regarded as attractive targets for the
design of a new generation of antiviral agents in recent years (32).
Recently, ST-148, a small molecule that potently inhibits in vitro
replication of all four serotypes of DENV, was identified (9). The
characterization of the mode of action of ST-148 showed that it
enhances capsid protein self-interaction, perturbing assembly and
disassembly of nucleocapsids (10). Importantly, the assays per-
formed in tissue culture and in infected mice exhibited no selec-
tion of ST-148-resistant viruses despite the presence of drug-
resistant variants in the population (11). The hypothesis of genetic
dominance of defective subunits proposes that oligomerization of
capsid units that include both resistant and susceptible proteins in
infected cells would generate nonfunctional complexes, causing a
delay in the emergence of resistant viruses (11). Thus, targeting
capsid functions is emerging as an attractive goal for developing
antivirals to control DENV infection.
Taking the results together, our work has provided new infor-
mation about the fate of viral nucleocapsid components during
DENV infection and has defined the requirement of ubiquitina-
tion, independently of the proteasome activity, for genome un-
coating. Hopefully, a better understanding of the host-virus inter-
action and the viral processes at the molecular level will provide
the necessary tools for DENV control.
MATERIALS AND METHODS
Cell lines and viruses.Baby hamster kidney cells (BHK-21)were cultured
inminimumessentialmediumalpha supplementedwith 10% fetal bovine
serum. Human lung cell line (A549) cells were cultured in Dulbecco’s
modified Eagle’s medium–Ham F-12 medium supplemented with 10%
fetal bovine serum. C6/36 HT mosquito cells from Aedes albopictus,
adapted to grow at 33°C, were cultured in L-15 medium (Leibovitz) sup-
plemented with 0.3% tryptose phosphate broth, 0.02% glutamine, 1%
modified Eagle’s medium (MEM) nonessential amino acid solution, and
10% fetal bovine serum. All media were supplemented with 100 U/ml
penicillin and 100g/ml streptomycin. Stocks of DENV serotype 2 16681
were prepared inmosquito C6/36 cells and used to infect the different cell
lines as indicated in each case.
Construction of recombinant DENVs. Dengue virus mutants were
generated using a DENV type 2 cDNA clone (pD2/IC) (33), with an ad-
ditional AflII restriction site just upstream of the polyprotein stop codon
and a NotI restriction site at nucleotide 244 (pD2/ICAflII-NotI). Muta-
tions were introduced into the full-length cDNAofDENV2 pD2/ICAflII,
replacing the SacI/NotI or NotI/SphI fragment of the WT plasmid with a
fragment derived from overlapping PCRmixtures containing the desired
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mutation as previously described (5). For reporter virus studies, the mu-
tations were introduced in the context of the DV-R virus (14).
RNA transcriptions and transfections.DENV genomic RNAwas ob-
tained by in vitro transcription using T7 RNA polymerase in the presence
of an m7GpppA cap analog. The corresponding plasmids were linearized
with XbaI and were purified by phenol-chloroform extraction. RNA in-
tegrity was confirmed using 1% agarose gels. RNA transfections were
performed with Lipofectamine 2000 (Invitrogen) according to the man-
ufacturer’s instructions. For reporter DENVs, 500 ng of RNA transcripts
was transfected into BHK-21, A549, or C6/36 HT cells grown in 24-well
plates. The Renilla luciferase activity present in cell extracts was analyzed
at the times indicated in the figures, according to the manufacturer’s in-
structions (Promega). The supernatants collected at the times indicated in
the figures were stored at 80°C. For indirect immunofluorescence (IF)
assays, 500 ng of RNA transcriptswas transfected intoBHK-21 cells grown
in 35-mm-diameter tissue culture dishes.
Immunofluorescence assays. Transfected BHK-21 cells with WT or
mutated DENV RNAs were grown in 35-mm-diameter tissue culture
dishes containing 1-cm2 coverslips. At various times posttransfection, the
coverslips were removed, and the cells were fixed with methanol for
15 min at 20°C. To maintain cell viability for a long time, cells were
trypsinized every 3 days, and a one-third volume of the total cells and the
supernatant was reseeded in a 35-mm-diameter tissue culture dish con-
taining a new coverslip. For the detection of viral antigens, a specific
anti-E monoclonal antibody (MAb) E18 (34) was used. Alexa Fluor 488-
conjugated rabbit anti-mouse immunoglobulin G (Molecular Probes)
was employed to detect the primary antibody under the same conditions.
Inhibitors.The compoundUBEI 41 (Pyr-41), a cell-permeable inhib-
itor of ubiquitin-activating enzyme (E1), was purchased from Sigma-
Aldrich, as well as the proteasome inhibitor MG-132. The concentrations
employed for assays were 75Mand 20M, respectively. Cycloheximide
(Sigma-Aldrich) was used at a concentration of 75 g/ml.
Western blotting.A549 cells infectedwithWTDENV2were grown in
35-mm-diameter tissue culture dishes. For the detection of capsid protein
in A549 cell extracts, cells were harvested in each experiment at the time
indicated, washed with phosphate-buffered saline (PBS), and treated
(when specified) with proteinase K (1 mg/ml) for 45 min at 4°C. The
proteinase K was inactivated (2 mM phenylmethylsulfonyl fluoride
[PMSF]–PBS–3% bovine serum albumin [BSA]), and the cells were lysed
using buffer H (10 mM HEPES [pH 7.9], 50 mM KCl, 2 mM EDTA,
0.5 mMPMSF, 1 mM dithiothreitol [DTT], 0.5 mMTriton X-100). Sam-
ples were analyzed by 15% SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) under denaturing conditions, and Western blotting was per-
formed using a specific rabbit anti-C polyclonal antibody obtained in our
laboratory as described previously (14).
RNA interference. RNA interference experiments were carried out
using ON-TARGETplus SMARTpool siRNA oligonucleotides (Dharma-
con RNA Technologies). RNA interference (RNA) was directed to UBA1
(7317) and UBA3 (9039). The control used was directed to Renilla lu-
ciferase and the unrelated siRNA to Firefly luciferase. After 24 h, the re-
action mixtures were seeded in 24-well plates and A549 cells were trans-
fected with the corresponding siRNA using Oligofectamine (Invitrogen).
Briefly, 25 pmol of siRNA and 50 l of Opti-MEM (Invitrogen) were
mixed with 2 l of Oligofectamine in 50 l of Opti-MEM and incubated
for 20 min. The mix was added to a monolayer of 50%-confluent A549
cells and incubated overnight. Then, the mediumwas replaced with com-
plete Dulbecco’s modified Eagle’s medium (DMEM)-F12 medium. After
48 h of transfection, cells were infected with DV-R and luciferase levels
were measured at 6 or 48 h.
RNA extraction, reverse transcription, and real-time PCR. For the
quantification of viral RNA by real-time reverse transcriptase PCR (RT-
PCR), the RNA from cells infected with DENV and treated with protei-
nase K was extracted with TRIzol (Invitrogen) at various times postinfec-
tion. RNA extracted from experimental samples was reverse transcribed
in 20-l reaction volumes using 160 units of Moloney murine leukemia
virus reverse transcriptase (M-MLV RT) (Promega), 4 units of RNasin
RNase inhibitors (Promega), 500 nM primer A.V.G. 572 (5= ACCAAGG
ACTCCTGCCTCTTCC 3=), 0.5 mM (each) deoxynucleoside triphos-
phates (dNTPs), and 1 M-MLV RT buffer. Primer and RNA template
were preincubated for 5 min at 70°C. The RT reaction was allowed to
proceed for 1 h at 42°C and then for 15 min at 65°C to denature the RT
enzyme. For real-time quantitative PCR (qPCR), anMx3005PQPCR sys-
tem (Agilent Technologies Inc.)was employed. Reactionswere performed
in triplicate in 96-well plates using 2 l of the RT reaction mixture as the
template (and a 1:10 dilution in RNase-free water), 5 l of FastStart Uni-
versal SYBR green Master (Rox) 2mix (Roche), 300 nM (each) primer
(5= GAATACACAGATTACATGCC 3= and A.V.G. 572), and RNase-free
water (added to reach a volume of 10 l). Reactions were run using the
following parameters: 95°C for 15min and 40 repeats of 95°C for 10 s and
60°C for 30 s. Fluorescence detection was acquired during the elongation
step at each cycle. Regarding the UBA1 and UBA3 qPCRs, the primers
used for amplification were UBA1 Fw (5= GATTTCATCGTGGCTGCAT
CCAAC 3=) and Rev (5= CTTGTAGGAGTCAAGCTGTCGGT 3=) and
UBA3 Fw (5= GATTTCATCGTGGCTGCATCCAAC 3=) and Rev (5= CT
ACCCCTTGAGTGAGCCTATAC 3=). The RT reaction was performed
with hexa-random primers.
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